The Randomized Etoricoxib Study in Patients With Osteoarthritis Not Responding to Analgesic Drugs - THE RESPOND-EUROPE STUDY.
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 16 Apr 2015
At a glance
- Drugs Etoricoxib (Primary)
- Indications Musculoskeletal pain; Osteoarthritis
- Focus Therapeutic Use
- Acronyms RESPOND-EUROPE
- Sponsors Merck Sharp & Dohme
- 15 Dec 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 09 Sep 2011 New trial record